RU2220968C2 - 2,6,9-тризамещенное производное пурина, фармацевтически приемлемая катионная соль, способ ингибирования пролиферации клеток, фармацевтическая композиция - Google Patents

2,6,9-тризамещенное производное пурина, фармацевтически приемлемая катионная соль, способ ингибирования пролиферации клеток, фармацевтическая композиция Download PDF

Info

Publication number
RU2220968C2
RU2220968C2 RU99104161/04A RU99104161A RU2220968C2 RU 2220968 C2 RU2220968 C2 RU 2220968C2 RU 99104161/04 A RU99104161/04 A RU 99104161/04A RU 99104161 A RU99104161 A RU 99104161A RU 2220968 C2 RU2220968 C2 RU 2220968C2
Authority
RU
Russia
Prior art keywords
group
lower alkyl
substituted
phenyl
hydrogen
Prior art date
Application number
RU99104161/04A
Other languages
English (en)
Russian (ru)
Other versions
RU99104161A (ru
Inventor
Роберт Т. ЛУМ (US)
Роберт Т. Лум
Чери Линн БЛУМ (US)
Чери Линн БЛУМ
Ричард МАКМАН (US)
Ричард Макман
Майкл М. ВИК (US)
Майкл М. Вик
Стивен Р. СКОУ (US)
Стивен Р. Скоу
Original Assignee
Си Ви Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Си Ви Терапьютикс, Инк. filed Critical Си Ви Терапьютикс, Инк.
Publication of RU99104161A publication Critical patent/RU99104161A/ru
Application granted granted Critical
Publication of RU2220968C2 publication Critical patent/RU2220968C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU99104161/04A 1996-08-02 1997-08-01 2,6,9-тризамещенное производное пурина, фармацевтически приемлемая катионная соль, способ ингибирования пролиферации клеток, фармацевтическая композиция RU2220968C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/692,012 US5866702A (en) 1996-08-02 1996-08-02 Purine inhibitors of cyclin dependent kinase 2
US08/692,012 1996-08-02

Publications (2)

Publication Number Publication Date
RU99104161A RU99104161A (ru) 2001-04-27
RU2220968C2 true RU2220968C2 (ru) 2004-01-10

Family

ID=24778922

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99104161/04A RU2220968C2 (ru) 1996-08-02 1997-08-01 2,6,9-тризамещенное производное пурина, фармацевтически приемлемая катионная соль, способ ингибирования пролиферации клеток, фармацевтическая композиция

Country Status (25)

Country Link
US (1) US5866702A (OSRAM)
EP (1) EP1021186B1 (OSRAM)
JP (1) JP2000515550A (OSRAM)
KR (1) KR100403336B1 (OSRAM)
CN (1) CN1161356C (OSRAM)
AT (1) ATE298572T1 (OSRAM)
AU (1) AU731778B2 (OSRAM)
BR (1) BR9710801A (OSRAM)
CA (1) CA2262454C (OSRAM)
CZ (1) CZ299381B6 (OSRAM)
DE (1) DE69733674T2 (OSRAM)
DK (1) DK1021186T3 (OSRAM)
ES (1) ES2242981T3 (OSRAM)
GE (1) GEP20022786B (OSRAM)
HU (1) HUP9902414A3 (OSRAM)
IL (1) IL128323A (OSRAM)
NO (1) NO323775B1 (OSRAM)
NZ (1) NZ334061A (OSRAM)
PL (1) PL189775B1 (OSRAM)
PT (1) PT1021186E (OSRAM)
RU (1) RU2220968C2 (OSRAM)
SI (1) SI1021186T1 (OSRAM)
TR (1) TR199900683T2 (OSRAM)
UA (1) UA71890C2 (OSRAM)
WO (1) WO1998005335A1 (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2461559C2 (ru) * 2007-04-04 2012-09-20 Сайкласел Лимитед Соединения
RU2481348C2 (ru) * 2007-05-04 2013-05-10 Астразенека Аб Химические соединения - 759
RU2506264C2 (ru) * 2009-04-03 2014-02-10 Вэрастэм, Инк. Пиримидин-замещенные пуриновые соединения в качестве ингибиторов киназы (или киназ)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9611157A (pt) * 1995-11-01 1999-03-30 Novartis Ag Derivados de purina e processos para sua preparação
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US6153618A (en) * 1996-10-11 2000-11-28 Chiron Corporation Inhibitors of glycogen synthase 3 kinase
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
JP2001509483A (ja) * 1997-07-12 2001-07-24 カンサー リサーチ キャンペーン テクノロジー リミテッド サイクリン依存性キナーゼ阻害性プリン誘導体
JP2001516694A (ja) * 1997-08-07 2001-10-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プロテインキナーゼ、ｇプロテイン及びポリメラーゼのプリン阻害剤
US6573044B1 (en) * 1997-08-07 2003-06-03 The Regents Of The University Of California Methods of using chemical libraries to search for new kinase inhibitors
WO1999032660A1 (en) * 1997-12-19 1999-07-01 Affymetrix Exploiting genomics in the search for new drugs
EP1418244A1 (en) * 1997-12-19 2004-05-12 Affymetrix, Inc. Exploiting genomics in the search for new drugs
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6642231B2 (en) * 1998-02-26 2003-11-04 Aventis Pharmaceuticals Inc. 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6703395B2 (en) 1998-03-04 2004-03-09 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
CA2231005A1 (en) 1998-03-04 1999-09-04 Libor Havlicek Cyclin dependent kinase inhibitor
GB9806739D0 (en) * 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
EP1086105B1 (en) * 1998-06-16 2006-03-01 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Fused azepinone cyclin dependent kinase inhibitors
US6531477B1 (en) 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
US6559152B2 (en) 1998-10-13 2003-05-06 Dupont Pharmaceuticals Company 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
KR100377138B1 (ko) * 1998-11-10 2003-06-12 주식회사 엘지생명과학 퓨린구조를갖는싸이클린의존키나아제저해제,그제조방법및그를함유하는항암제조성물
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
AU2004200192B2 (en) * 1999-02-01 2006-11-16 Gilead Palo Alto, Inc. Purine inhibitors of cyclin dependent kinase 2 and 1k-Aa
DE60023268T2 (de) * 1999-02-01 2006-06-01 CV Therapeutics, Inc., Palo Alto INHIBITEURS PURIQUES DE KINASE 2 DEPENDANTE DES CYCLINES et IkB-alpha
KR100368515B1 (ko) * 1999-02-03 2003-01-24 주식회사 엘지생명과학 싸이클린 의존 키나아제 저해제 및 그의 제조 방법
KR20000055080A (ko) * 1999-02-03 2000-09-05 성재갑 싸이클린 의존 키나아제 저해제 및 그의 제조 방법
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6627633B2 (en) * 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
US6969720B2 (en) 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
CA2377085C (en) * 1999-06-23 2011-02-15 Aventis Pharma Deutschland Gmbh Substituted benzimidazoles
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
EP1248790A1 (en) * 1999-12-17 2002-10-16 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
US20030187261A1 (en) * 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
KR20010077073A (ko) * 2000-01-31 2001-08-17 박호군 Ｃ-２,６,９ 위치에 치환된 이소프로필퓨린 유도체 및그의 제조 방법
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
JP2004516297A (ja) * 2000-12-20 2004-06-03 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） サイクリン依存性キナーゼ（ｃｄｋ）及びグリコーゲンシンターゼキナーゼ−３（ｇｓｋ−３）の阻害剤
FR2818278B1 (fr) * 2000-12-20 2003-02-28 Sod Conseils Rech Applic Inhibiteurs de kinases dependantes des cyclines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US7605175B2 (en) 2001-03-02 2009-10-20 Gpc Biotech Ag Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
US6812232B2 (en) 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
CA2463563A1 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
WO2003051882A1 (en) * 2001-12-18 2003-06-26 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
ES2276084T3 (es) * 2002-02-15 2007-06-16 Cv Therapeutics, Inc. Revestimiento polimerico para dispositivos medicos.
JP4725944B2 (ja) 2002-03-13 2011-07-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの阻害剤
EP1485354B1 (en) 2002-03-13 2008-05-28 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
CA2501999A1 (en) * 2002-10-15 2004-04-29 Irm Llc Compositions and methods for inducing osteogenesis
CA2521854C (en) 2003-04-07 2011-11-01 Gpc Biotech, Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
KR100573861B1 (ko) * 2003-07-18 2006-04-25 경동제약 주식회사 2-아미노-9-(2-할로게노에틸)푸린 및 그 중간체로서의 2-아미노-6,8-디클로로-9-(2-히드록시에틸)푸린의 제조방법
CN100447143C (zh) * 2003-08-15 2008-12-31 Irm责任有限公司 作为rtk抑制剂的6-取代的苯胺基嘌呤
WO2005016528A2 (en) * 2003-08-15 2005-02-24 Irm Llc 6-substituted anilino purines as rtk inhibitors
CA2535313C (en) * 2003-09-25 2012-07-17 Janssen Pharmaceutica N.V. Hiv replication inhibiting purine derivatives
EA013117B1 (ru) 2003-12-23 2010-02-26 ДжиПиСи БАЙОТЕК, ИНК. Ингибиторы циклинзависимых киназ, относящиеся к ним композиции и применения
JP2006056879A (ja) * 2004-07-21 2006-03-02 Kobe Univ インスリン抵抗性の改善剤、及びそのスクリーニング方法
EA010652B1 (ru) 2004-07-28 2008-10-30 Янссен Фармацевтика Н.В. Замещенные индолильные алкиламинопроизводные в качестве новых ингибиторов гистондеацетилазы
ES2403558T3 (es) * 2004-08-27 2013-05-20 Cyclacel Limited Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias
GB0419175D0 (en) * 2004-08-27 2004-09-29 Cyclacel Ltd Method of treatment and compositions
WO2006040036A1 (en) 2004-10-13 2006-04-20 F. Hoffmann-La Roche Ag Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2006051951A1 (ja) * 2004-11-12 2006-05-18 Kazuhito Tomizawa Cdk5阻害剤を含む糖尿病治療薬
KR100677396B1 (ko) * 2004-11-20 2007-02-02 엘지전자 주식회사 음성인식장치의 음성구간 검출방법
AU2006215386B2 (en) * 2005-02-16 2009-06-11 Astrazeneca Ab Chemical compounds
JP5108752B2 (ja) * 2005-05-16 2012-12-26 プロメティック・バイオサイエンスィズ・インコーポレーテッド 自己免疫疾患を治療するための化合物とそれら化合物の使用
EP1940843A4 (en) * 2005-08-11 2010-09-15 Ariad Pharma Inc UNSATURATED HETEROCYCLIC DERIVATIVES
CN101360494A (zh) * 2005-11-22 2009-02-04 斯克里普斯研究学院 高效埃博霉素的化学合成
CA2630717C (en) 2006-01-19 2015-02-24 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
BRPI0707312B1 (pt) 2006-01-27 2022-06-07 Shanghai Hengrui Pharmacetical Co., Ltd Inibidores de pirrolo [3,2-c] piridina-4-ona 2-indolinona proteína cinase, seu uso e seu processo de fabricação, intermediário e seus processos de fabricação, composição farmacêutica e seu uso
GB0606283D0 (en) * 2006-03-29 2006-05-10 Cyclacel Ltd Process
US8835426B2 (en) * 2007-02-26 2014-09-16 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1
WO2008135232A1 (en) * 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
WO2008138232A1 (en) 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co., Ltd. Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof
WO2008138184A1 (fr) 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
CA2697147A1 (en) * 2007-07-26 2009-02-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
FR2920776B1 (fr) * 2007-09-12 2012-09-28 Centre Nat Rech Scient Utilisation de derives de purine pour la fabrication d'un medicament
JP5638955B2 (ja) * 2007-10-26 2014-12-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｐｉ３キナーゼ阻害剤として有用なプリン誘導体
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
EP2252601B1 (en) * 2008-01-24 2012-12-19 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5734666B2 (ja) * 2008-02-11 2015-06-17 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の１，３−オキサアゼパン−２−オン及び１，３−ジアゼパン−２−オン阻害剤
EP2254872A2 (en) * 2008-02-15 2010-12-01 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CA2718264A1 (en) * 2008-03-18 2009-09-24 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
EP2291373B1 (en) * 2008-05-01 2013-09-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
KR20110002492A (ko) * 2008-05-01 2011-01-07 비타이 파마슈티컬즈, 인코포레이티드 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
AR071236A1 (es) 2008-05-01 2010-06-02 Vitae Pharmaceuticals Inc Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
US8592410B2 (en) 2008-05-01 2013-11-26 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1
JP2011521968A (ja) * 2008-05-30 2011-07-28 ジェネンテック， インコーポレイテッド プリンｐｉ３ｋ阻害剤化合物および使用方法
CN104193740A (zh) 2008-07-03 2014-12-10 西特里斯药业公司 作为沉默调节蛋白调节剂的苯并咪唑类和相关的类似物
RU2539979C2 (ru) 2008-07-25 2015-01-27 Вайтаи Фармасьютиклз, Инк. Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1
WO2010010157A2 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1
WO2010056311A1 (en) 2008-11-12 2010-05-20 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
WO2010089303A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1
US8592415B2 (en) 2009-02-11 2013-11-26 Reaction Biology Corp. Selective kinase inhibitors
WO2010103473A1 (en) * 2009-03-10 2010-09-16 Chu De Brest Method of treatment of polycystic diseases and chronic lymphocytic leukemia
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
GEP20156309B (en) * 2009-04-30 2015-07-10 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2011011123A1 (en) 2009-06-11 2011-01-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
SG177384A1 (en) 2009-06-29 2012-02-28 Incyte Corp Pyrimidinones as pi3k inhibitors
EP2448928B1 (en) 2009-07-01 2014-08-13 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8759359B2 (en) * 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
TW201130842A (en) * 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2011106168A1 (en) * 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
JP5816678B2 (ja) 2010-04-14 2015-11-18 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ＰＩ３Ｋδ阻害剤としての縮合誘導体
US9376664B2 (en) 2010-06-14 2016-06-28 The Scripps Research Institute Reprogramming of cells to a new fate
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
EP2585444B1 (en) 2010-06-25 2014-10-22 Boehringer Ingelheim International GmbH Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
EP2593455B1 (en) 2010-07-14 2015-03-18 F.Hoffmann-La Roche Ag Purine compounds selective for i3 p110 delta, and methods of use
US8969556B2 (en) * 2010-10-12 2015-03-03 Case Western Reserve University Purine-based triazoles
EP2635268A1 (en) 2010-11-02 2013-09-11 Boehringer Ingelheim International GmbH Pharmaceutical combinations for the treatment of metabolic disorders
SG10201510347QA (en) 2010-12-16 2016-01-28 Hoffmann La Roche Tricyclic pi3k inhibitor compounds and methods of use
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
MY179332A (en) 2011-09-02 2020-11-04 Incyte Holdings Corp Heterocyclylamines as pl3k inhibitors
BR112014006840A2 (pt) * 2011-09-22 2017-04-04 Pfizer derivados de pirrolopirimidina e purina
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
WO2013113762A1 (en) 2012-01-31 2013-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2664619B1 (en) * 2012-05-16 2017-07-12 Manros Therapeutics Purine derivatives as tools for screening anti-Alzheimer compounds
FR3011240A1 (fr) 2013-10-01 2015-04-03 Centre Nat Rech Scient Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
CN105849099B (zh) 2013-10-18 2020-01-17 达纳-法伯癌症研究所股份有限公司 周期蛋白依赖性激酶7(cdk7)的多环抑制剂
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
CN104086551B (zh) * 2014-06-06 2016-09-21 人福医药集团股份公司 化合物及其制备方法和用途
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3831833B1 (en) 2015-02-27 2022-10-26 Incyte Holdings Corporation Processes for the preparation of a pi3k inhibitor
JP6861166B2 (ja) * 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10045981B2 (en) 2015-11-24 2018-08-14 Jakpharm, Llc Selective kinase inhibitors
EP3388432A1 (en) 2017-04-10 2018-10-17 Commissariat à l'Energie Atomique et aux Energies Alternatives Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders
AU2019277560B2 (en) 2018-06-01 2025-04-24 Incyte Corporation Dosing regimen for the treatment of PI3K related disorders
CA3099763A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
WO2023140640A1 (ko) * 2022-01-21 2023-07-27 한양대학교 산학협력단 헤테로아릴 유도체 및 이의 용도
CN117659016A (zh) * 2022-08-26 2024-03-08 嘉兴优博生物技术有限公司 细胞周期蛋白调节剂
TW202440578A (zh) 2022-12-16 2024-10-16 瑞典商阿斯特捷利康公司 ２，６，９－三取代嘌呤
CN116813621A (zh) * 2023-06-08 2023-09-29 江南大学 9h嘌呤类化合物及其药物组合物和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035095A1 (en) * 1994-06-22 1995-12-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for applying active substances to or through the skin
RU2067097C1 (ru) * 1988-01-20 1996-09-27 Риджентс Оф Дзе Юниверсити Оф Миннесота Способ получения дидезоксидидегидрокарбоциклических нуклеозидов
RU2068849C1 (ru) * 1989-12-22 1996-11-10 Дзе Веллкам Фаундейшн Лимитед Способ получения энантиомерных соединений или их производных

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028353A (en) * 1971-07-29 1977-06-07 Polaroid Corporation Novel chemical compounds
US4028358A (en) * 1973-09-04 1977-06-07 Liotta Charles L 6-Fluoro-9-perfluorobutyl purine
US4405781A (en) * 1981-03-02 1983-09-20 Polaroid Corporation Method for preparing salts of 6-chloropurine
FI94133C (fi) * 1985-04-19 1995-07-25 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten griseoliinihapon johdannaisten valmistamiseksi
GB9204015D0 (en) * 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
FR2699176B1 (fr) * 1992-12-11 1995-03-03 Adir Nouveaux composés bicycliques de pyrimidine, leur procédé de préparation et les compositions pharmaceutiques les renfermant.
BR9611157A (pt) * 1995-11-01 1999-03-30 Novartis Ag Derivados de purina e processos para sua preparação
EP0802914B1 (en) * 1995-11-14 2001-06-06 PHARMACIA & UPJOHN S.p.A. Aryl- and heteroaryl- purine and pyridopyrimidine derivatives
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2067097C1 (ru) * 1988-01-20 1996-09-27 Риджентс Оф Дзе Юниверсити Оф Миннесота Способ получения дидезоксидидегидрокарбоциклических нуклеозидов
RU2068849C1 (ru) * 1989-12-22 1996-11-10 Дзе Веллкам Фаундейшн Лимитед Способ получения энантиомерных соединений или их производных
WO1995035095A1 (en) * 1994-06-22 1995-12-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for applying active substances to or through the skin

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2461559C2 (ru) * 2007-04-04 2012-09-20 Сайкласел Лимитед Соединения
RU2481348C2 (ru) * 2007-05-04 2013-05-10 Астразенека Аб Химические соединения - 759
RU2506264C2 (ru) * 2009-04-03 2014-02-10 Вэрастэм, Инк. Пиримидин-замещенные пуриновые соединения в качестве ингибиторов киназы (или киназ)

Also Published As

Publication number Publication date
HUP9902414A3 (en) 2002-04-29
DE69733674D1 (de) 2005-08-04
ATE298572T1 (de) 2005-07-15
EP1021186A4 (en) 2000-07-26
CA2262454C (en) 2006-02-07
HUP9902414A2 (hu) 2001-04-28
NZ334061A (en) 2000-08-25
NO990466L (no) 1999-03-25
AU3900097A (en) 1998-02-25
KR100403336B1 (ko) 2003-10-30
HK1020884A1 (en) 2000-05-26
NO323775B1 (no) 2007-07-02
DK1021186T3 (da) 2005-10-17
NO990466D0 (no) 1999-02-01
CZ299381B6 (cs) 2008-07-09
UA71890C2 (en) 2005-01-17
WO1998005335A1 (en) 1998-02-12
AU731778B2 (en) 2001-04-05
PT1021186E (pt) 2005-11-30
CA2262454A1 (en) 1998-02-12
CN1231611A (zh) 1999-10-13
ES2242981T3 (es) 2005-11-16
GEP20022786B (en) 2002-09-25
US5866702A (en) 1999-02-02
EP1021186A1 (en) 2000-07-26
SI1021186T1 (sl) 2005-12-31
PL189775B1 (pl) 2005-09-30
DE69733674T2 (de) 2006-05-04
IL128323A (en) 2001-11-25
IL128323A0 (en) 2000-01-31
BR9710801A (pt) 2001-11-27
TR199900683T2 (xx) 2002-01-21
PL331408A1 (en) 1999-07-19
CZ33899A3 (cs) 2000-03-15
CN1161356C (zh) 2004-08-11
EP1021186B1 (en) 2005-06-29
KR20000029781A (ko) 2000-05-25
JP2000515550A (ja) 2000-11-21

Similar Documents

Publication Publication Date Title
RU2220968C2 (ru) 2,6,9-тризамещенное производное пурина, фармацевтически приемлемая катионная соль, способ ингибирования пролиферации клеток, фармацевтическая композиция
RU2001107897A (ru) Фармацевтическая композиция для лечения гепатита
CA2491632A1 (en) Pyrimidinylaminobenzamide derivatives and their use as inhibitors of tyrosine kinases
KR960034203A (ko) 고리 화합물, 그의 제조 및 용도
EP1790344A2 (en) Methods for treatment of disease-induced peripheral neuropathy and related conditions
RU99104161A (ru) ПУРИНОВЫЕ ИНГИБИТОРЫ ЦИКЛИН-ЗАВИСИМОЙ КИНАЗЫ 2 И IKВ-α
WO1996013512B1 (en) L-ribofuranosyl nucleosides
JPH08259567A (ja) ピラゾロピリミジン類およびピロロピリミジン類によるニューロン疾患およびその他疾患の治療方法
ES2173074T3 (es) Derivados de xantina, procedimiento para su preparacion y su uso farmaceutico.
KR930702292A (ko) 종양 치료 활성을 증대시키기 위한 퀴나졸린 유도체
KR880009984A (ko) 아데노신 5'-카복사미드 유도체
KR900004333A (ko) 맥관 형성 억제제
PT98358A (pt) Processo para a preparacao de novos compostos pirazolopiridinicos
JP2007503443A5 (OSRAM)
RU93004423A (ru) Производное хиназолина, способ его получения, фармацевтическая композиция на его основе и применение
RU99104152A (ru) Циклические аминопроизводные
RU96107113A (ru) C-22 циклические стабилизированные производные рапамицина
CA2436891A1 (en) Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors
RU2003117406A (ru) Средство для лечения желудочно-кишечных опухолей
KR960014102A (ko) 인돌로일구아니딘 유도체
BR1100636A (pt) Agente terapêutico para o mal de parkinson, e, derivado da xantina
KR960007565A (ko) 약제로서의 치환된 4-페닐-6-아미노-니코틴산 유도체의 용도
KR900018112A (ko) 흥분성 아미노산 길항제
NO169894C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrahydronaftalen-forbindelser
KR910004568A (ko) 치환 n-(퀴놀린-2-일-메톡시)벤질-술포닐우레아

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20100802